Bristol-Myers Squibb Co. (BMY) Social Stream
Bristol Myers Squibb Co (BMY) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering Bristol Myers Squibb Co.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-09 | 14 | $80 | $66 | $73.222 | $73.79 | -0.77% |
| 2021-11-17 | 13 | $80 | $66 | $72.875 | $73.79 | -1.24% |
| 2021-11-18 | 12 | $80 | $66 | $72.875 | $73.79 | -1.24% |
| 2021-11-19 | 12 | $80 | $66 | $72.777 | $73.79 | -1.37% |
| 2022-02-07 | 13 | $80 | $58 | $71.3 | $73.79 | -3.37% |
| 2022-03-25 | 13 | $80 | $58 | $71.5 | $73.79 | -3.1% |
| 2022-03-30 | 13 | $81 | $58 | $72.4 | $73.79 | -1.88% |
The Trend in the Analyst Price Target
Over the past 43 weeks, BMY's average price target has gone down $2.97.
Over the past 51 weeks, BMY's average upside potential has been 14.94%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-05-08 | 19 | 89 | 62 | 75.44 | 64.44 | 17.07% |
| 2021-06-26 | 19 | 90 | 62 | 75.37 | 66.74 | 12.93% |
| 2021-07-03 | 19 | 90 | 62 | 75.37 | 66.95 | 12.58% |
| 2021-08-28 | 19 | 94 | 66 | 77.01 | 66.60 | 15.63% |
| 2022-02-07 | 13 | 80 | 58 | 71.30 | 66.19 | 7.72% |
BMY Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2 | 6 | 1 | 6 | 0 | 0 | 13 |
The Trend in the Broker Recommendations
BMY's average broker recommendation rating worsened by 0.1 over the prior 15 months.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for BMY as an investment opportunity.
- Bristol Myers Squibb Co's upside potential (average analyst target price relative to current price) is greater than 102.53% of all US stocks.
- BMY has a higher number of analysts covering the stock than 703.95% of Pharmaceutical Products stocks.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, Bristol Myers Squibb Co's variance in analysts' estimates is lower than -42.18% of them.
- In terms of how Bristol Myers Squibb Co fares relative to Pharmaceutical Products stocks, note that its average analyst price target is greater than 639.91% of that group.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Bristol Myers Squibb Co are BMRN, BHC, and BGNE.
Is BMY a Buy, Hold or Sell? See the POWR Ratings now!